PTC Therapeutics has withdrawn its New Drug Application resubmission for Translarna following feedback from the US Food and Drug Administration. Translarna is an investigational therapy for nonsense ...

A new gene therapy developed by researchers at the University of Missouri School of Medicine has been shown to protect mice from a life-threatening heart condition caused by muscular dystrophy. UT ...

When Conner Curran was first diagnosed with Duchenne muscular dystrophy at age 4, his parents were told there was nothing they could do to change his life's course. Jessica and Chris should enjoy ...

A retrospective cohort study found that, among 459 patients with DMD, constipation (32.5%) was the most common GI complication, followed by dysphagia (9.4%). Older age, lower body mass index, and use ...

Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, ...

These investigators enrolled 60 bisphosphonate-naïve males ages 4 to 25 years old treated with glucocorticoids for genetically confirmed Duchenne muscular dystrophy. After 22 patients were excluded ...

DAYTON, Ohio (WDTN) — Ohio will be the first in the nation to screen newborn babies for a rare muscular condition. Gov. Mike DeWine announced this week that Ohio will begin screening all newborn ...

To help neurologists, clinicians and families understand the current evidence for a new gene therapy for Duchenne muscular dystrophy called delandistrogene moxeparvovec, the American Academy of ...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, ...

Duchenne muscular dystrophy (DMD) is one of the most common and most devastating muscular diseases, greatly reducing patients’ quality of life and life expectancy. Now, researchers in Germany have ...